IGM Biosciences. has filed a patent for isolated anti-PD-L1 antibodies for treating diseases mediated by PD-L1 signaling. The claim specifies polynucleotides encoding specific antibody chains with defined sequences. GlobalData’s report on IGM Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights IGM Biosciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on IGM Biosciences, Personalized cancer vaccines was a key innovation area identified from patents. IGM Biosciences's grant share as of January 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.

Anti-pd-l1 antibody for treating diseases mediated by pd-l1 signaling

Source: United States Patent and Trademark Office (USPTO). Credit: IGM Biosciences Inc

A patent application (Publication Number: US20240002514A1) discloses a polynucleotide encoding a heavy chain or light chain of an anti-PD-L1 antibody or antigen-binding fragment. The heavy chain must have at least 90% sequence identity to specific sequences, while the light chain must also meet similar criteria. The antibody or fragment includes specific sequences for HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3. Various claims detail the specific amino acid sequences and isotypes of the antibody, as well as the use of vectors and host cells for production.

Furthermore, the patent application outlines a method for producing the anti-PD-L1 antibody or fragment by culturing a host cell with specific polynucleotides and isolating the antibody from the culture. The method specifies the sequences required for the heavy and light chains, as well as the possibility of creating chimeric or humanized antibodies. Additionally, the method covers the production of bispecific antibodies that bind to both PD-L1 and a cell surface protein, with options for different isotypes and antigen-binding fragments. The method also includes steps for transfecting the host cell with specific polynucleotides, including a modified J-chain with an extraneous binding moiety.

To know more about GlobalData’s detailed insights on IGM Biosciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies